Cellectar Reports Financial Results for Year Ended December 31, 2020 and Provides a Corporate Update Mar 2, 2021
Cellectar Receives Orphan Drug Designation from the European Commission for CLR 131 in Waldenstrom’s Macroglobulinemia Jan 27, 2021
Cellectar Biosciences Announces Closing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement Dec 28, 2020
Cellectar Biosciences Announces Pricing of $24.5 Million Underwritten Public Offering and $20.5 Million Concurrent Private Placement Dec 23, 2020
Cellectar Biosciences Announces Proposed Underwritten Public Offering and Concurrent Private Placement Dec 22, 2020
Cellectar Biosciences’ CLR 131 Demonstrates Preliminary Activity in Phase I Study for Pediatric Brain and Solid Tumors Nov 5, 2020